Verastem Oncology announces initial data from TARGET-D 101 trial of VS-7375

Verastem Oncology announced initial data from the first multi-tumor update of its ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, reporting robust clinical activity with a favorable safety and tolerability profile across multiple dose levels and tumor types.

Detected & updated continuously · Source: Nebula